Cibus to Report First Quarter 2025 Financial Results on May 8, 2025 After the Market Close and Host Conference Call

Rhea-AI Summary

Cibus (Nasdaq: CBUS), a leading agricultural biotechnology company specializing in proprietary gene editing technologies for plant trait development in seeds, has scheduled its first quarter 2025 financial results announcement for Thursday, May 8, 2025 after market close.

The company will host a conference call and audio webcast at 4:30 p.m. ET to discuss financial results and company updates. Participants can join via phone using U.S. (+1-833-316-1983) or International (+1-785-838-9310) numbers with conference ID 'CIBUS' or 24287.

A replay will be available through May 22, 2025, and the webcast with slides will be accessible on the company's investor website for 90 days after the event.

SAN DIEGO, April 25, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that the company will report first quarter 2025 financial results on Thursday, May 8, 2025. Cibus’ management team will host a conference call and audio webcast at 4:30 p.m. ET on that day to discuss the financial results and other company updates.

Title: Cibus, Inc. First Quarter 2025 Results Conference Call
Event Date: Thursday, May 8, 2025
Time: 4:30 p.m. ET
Participant Numbers: +1-833-316-1983 (U.S.), +1-785-838-9310 (International)
The conference ID “CIBUS” or 24287 will be required for entry
Event Link: https://investor.cibus.com/events

For interested individuals unable to join the conference call, a dial-in replay of the call will be available through Thursday, May 22, 2025 and can be accessed by dialing +1-844-512-2921 (U.S.), +1-412-317-6671 (International) and entering replay passcode: 11158792.

A live audio webcast of the call, along with accompanying slides, will be available under "News & Events” in the Investor section of the Company's website, investor.cibus.com. An archived webcast will be available on the Company's website for 90 days after the event.

About Cibus

Cibus is a leader in gene edited productivity traits that address critical productivity and sustainability challenges for farmers such as diseases and pests which the United Nations estimates cost the global economy approximately $300 billion annually. Cibus is not a seed company. It is a technology company that uses gene editing to develop and license traits to seed companies in exchange for royalties on seed sales. Cibus' long-term focus is productivity traits for farmers for the major global row crops with large acreage such as canola, corn, rice, soybean, and wheat. Cibus is a technology leader in high-throughput gene editing technology that is expected to enable it to develop and commercialize plant traits at a fraction of the time and cost of conventional breeding. Cibus has developed a current pipeline of five productivity traits including important traits for weed management in Rice, Pod Shatter Reduction, and Sclerotinia (disease) resistance, which are its near-term focus.

Cibus Contacts:

Investor Relations
Karen Troeber
ktroeber@cibus.com
858-450-2636

Jeff Sonnek – ICR
jeff.sonnek@icrinc.com

Media Relations
Colin Sanford
colin@bioscribe.com
203-918-4347

FAQ

When will Cibus (CBUS) report Q1 2025 earnings?

Cibus will report its Q1 2025 financial results on Thursday, May 8, 2025, after the market close.

How can I join the Cibus (CBUS) Q1 2025 earnings call?

Join via phone at 4:30 p.m. ET using U.S. number +1-833-316-1983 or International +1-785-838-9310 with conference ID 'CIBUS' or 24287, or through the webcast at investor.cibus.com.

How long will Cibus (CBUS) Q1 2025 earnings call replay be available?

The earnings call replay will be available until May 22, 2025, and the webcast recording will be accessible for 90 days on the company's website.

What is Cibus's (CBUS) main business focus?

Cibus is an agricultural biotechnology company that develops plant traits in seeds using proprietary gene editing technologies.